Cargando…
Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
Immune checkpoint inhibitors (ICIs) have become a new hope for many patients with advanced cancer by blocking tumour immune evasion. However, with the widespread use of ICIs, immune‐related adverse events (irAEs) have also been discovered and reported increasingly. Immune‐related myocarditis, the mo...
Autores principales: | Liu, Zhijie, Fan, Yiming, Guo, Jun, Bian, Ning, Chen, Dongdong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065848/ https://www.ncbi.nlm.nih.gov/pubmed/35322589 http://dx.doi.org/10.1002/ehf2.13912 |
Ejemplares similares
-
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019) -
Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021) -
Delayed Diagnosis and Recovery of Fulminant Immune Checkpoint Inhibitor-Associated Myocarditis on VA-ECMO Support
por: Ramayya, Tarun, et al.
Publicado: (2022) -
Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
por: Barham, Whitney, et al.
Publicado: (2021) -
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022)